A novel UPLC/MS/MS method for rapid determination of metapristone in rat plasma, a new cancer metastasis chemopreventive agent derived from mifepristone (RU486)

Journal of Pharmaceutical and Biomedical Analysis

Volumn 95, Issue , 2014, Pages 158-163

  Chen, Jian Zhong ^a,b   Wang, Ji Chuang ^a   Gao, Yu ^a   Zeng, Rong Jie ^b   Jiang, Zhou ^a   Zhu, Ye Wei ^a   Shao, Jing Wei ^a   Jia, Lee ^a  

^a FUZHOU UNIVERSITY   (China)

^b FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cancer metastasis chemopreventive agent; Metapristone; Mifepristone; Pharmacokinetics; UPLC MS MS

Indexed keywords

ACETIC ACID ETHYL ESTER; ANTINEOPLASTIC AGENT; FORMIC ACID; LEVONORGESTREL; METAPRISTONE; METHANOL; MIFEPRISTONE; UNCLASSIFIED DRUG; WATER;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; ELECTROSPRAY; FEMALE; FLOW RATE; LIMIT OF QUANTITATION; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA VOLUME; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; ANTICARCINOGENIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; LIMIT OF DETECTION; MALE; MIFEPRISTONE; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY;

EID: 84896967263     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.02.026     Document Type: Article

References (17)

1. Sitruk-Ware R., Spitz I.M. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception 2003, 68:409-420.
2. Heikinheimo O., Kontula K., Croxatto H., Spitz I., Luukkainen T., Lahteenmaki P. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J. Steroid Biochem. 1987, 26:279-284.
3. Shi Y.E., Ye Z.H., He C.H., Zhang G.Q., Xu J.Q., Van Look P.F., Fotherby K. Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women. Contraception 1993, 48:133-149.
4. Tang C., Bi H.C., Zhong G.P., Chen X., Huang Z.Y., Huang M. Simultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography-tandem mass spectrometry method using levonorgestrel as an internal standard: application to a pharmacokinetic study. Biomed. Chromatogr. 2009, 23:71-80.
5. Teng Y.N., Dong R.Q., Wang B.J., Liu H.J., Jiang Z.M., Wei C.M., Zhang R., Yuan G.Y., Liu X.Y., Guo R.C. Determinations of mifepristone and its metabolites and their pharmacokinetics in healthy female Chinese subjects. Acta Pharm. Sin. 2011, 46:1241-1245.
6. Wang J.C., Chen J.Z., Shao J.W., Wang L.Y., Lu Y.S., Zhu Y.W., Ou M.R., Yu S.H., Chen H.J., Jia L. Synthesis, spectral characterization and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486). AAPS J. 2014, 16:289-298.
7. Liu X., Jia L. The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies. Curr. Drug Metab. 2007, 8:815-821.
8. Kawai S., Nieman L.K., Brandon D.D., Udelsman R., Loriaux D.L., Chrousos G.P. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. J. Pharmacol. Exp. Ther. 1987, 241:401-406.
9. Foldesi I., Falkay G., Kovacs L. Determination of RU486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study. Contraception 1996, 54:27-32.
10. Leminen R., Ranta S., von Hertzen H., Oehler J., Heikinheimo O. Pharmacokinetics of 10mg of mifepristone. Contraception 2003, 68:427-429.
11. Guo Z., Chu C., Yin G., He M., Fu K., Wu J. An HPLC method for the determination of ng mifepristone in human plasma. J. Chromatogr: B Analyt. Technol. Biomed. Life Sci. 2006, 832:181-184.
12. Wei Y., Zhang M., Wang K., Zhao Z., Shao Q. Pharmacokinetics of mifepristone after low oral dose in healthy Chinese women. Chin. J. Clin. Pharmacol. 2003, 19:430-433.
13. Chen J.Z., Xu Y., Chou G.X., Wang C.H., Yang L., Wang Z.T. Simultaneous determination of norisoboldine and its major metabolite in rat plasma by ultra-performance liquid chromatography-mass spectrometry and its application in a pharmacokinetic study. Biomed. Chromatogr. 2011, 25:367-372.
14. Chen J.Z., Li Y., Xiao J.P., Wu S.S., Song H.W. Development of a sensitive and rapid UPLC-MS/MS method for the determination of koumine in rat plasma: application to a pharmacokinetic study. Biomed. Chromatogr. 2013, 27:736-740.
15. Jiang Z., Shao J., Chen M., Wang J., Jia L. A novel SPE-HPLC method for simultaneous determination of selected sulfonated phthalocyanine zinc complexes in mouse plasma following cassette dosing. Analyst 2013, 138:4385-4392.
16. Jia L., Linnik M.D., Jack R.M., Yu L. Biostability and pharmacokinetics of LJP 920, an octameric Gal (alpha1-3) Gal conjugate for the inhibition of xenotransplantation rejection. J. Pharm. Pharmacol. 2001, 53:999-1005.
17. Gorman G.S., Coward L.U., Freeman L., Noker P.E., Beattie C.W., Jia L. A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice. J. Pharm. Biomed. Anal. 2010, 53:991-996.